Cutera announces a new U.S. Food and Drug Administration Clearance of AviClear as a long-term treatment for mild to severe inflammatory acne vulgaris. This is the first acne therapy to claim long term effectiveness for mild, moderate and severe acne.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on CUTR:
- SetPoint Medical names Cutera CFO Rohan Seth as new CFO
- Is CUTR a Buy, Before Earnings?
- Short Report: Bears boost Vivid Seats position to record high as stock bottoms
- Jefferies med supplies/devices analyst holds analyst/industry conference call
- Plants, Mowry say Cutera special committee made ‘misleading’ statements